Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trasylol Safety Review Raises Questions About Role Of Observational Data

Executive Summary

FDA continues to grapple with the relative benefits of observational data and randomized controlled trials to evaluate drug safety
Advertisement

Related Content

Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Bayer Trasylol Being Pulled From Market After BART Trial Fails As Tourniquet
Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
Trasylol Linked To Increased Long-Term Mortality In CABG Patients – JAMA
Trasylol Linked To Increased Long-Term Mortality In CABG Patients – JAMA
Seeing the value in observational studies
Seeing the value in observational studies
Advertisement
UsernamePublicRestriction

Register

PS047633

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel